In March 2021, Biomapas started an EU-funded project, “Health solution for COVID-19 disease research, monitoring, and treatment “.
The project’s main aim is to develop an innovative eHealth system for the research and treatment of COVID-19 disease.
Biomapas seeks to create this electronic solution to manage the COVID-19 disease treatment process effectively during the project implementation period. It will facilitate the usual study, observation, and treatment methods to further research the disease effects and its consequences. The created prototype will be tested in a clinical trial to ensure effectiveness and safety.
Project implementation period: March 2021 – February 2022.
The project is co-financed by European Regional Development Fund up to € 1 000 000.
In July 2020, Biomapas started an EU-funded project of research and development activities by creating an artificial intelligence (AI) tool for pharmacovigilance services.
The main aim of the project – to create a pharmacovigilance system based on artificial intelligence.
Biomapas plans to commercialize the prototype of the technology created during the project in the form of a new pharmacovigilance service, ensuring continuous improvement of drug safety. It is planned that this service will be available on the market within a few months after completing the project. The company hopes that the new service will allow it to gain a fairly significant market share in the global market.
Project implementation period: July 2020 – June 2023.
The project is co-financed by European Regional Development Fund up to € 1 093 434,66.
In January 2017, Biomapas became active in an EU-funded project of strengthening international competitiveness by raising awareness in foreign markets.
Biomapas attended eight International Events/Exhibitions to introduce its services to key market players for current cooperation and share business development strategies by creating relationships for future collaboration.
EU funding for the project was 50% of the costs.